Functional characterization of mutant androgen receptors from androgen- independent prostate cancer

Clinical Cancer Research

Volumn 3, Issue 8, 1997, Pages 1383-1388

  Fenton, Mary Anne ^a   Shuster, Todd D ^a   Fertig, Alexis M ^a   Taplin, Mary Ellen ^b   Kolvenbag, Geert ^c   Bubley, Glenn J ^a   Balk, Steven P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; NILUTAMIDE;

ANIMAL CELL; ARTICLE; DRUG RESPONSE; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BLOCKING;

AMINO ACID SUBSTITUTION; ANDROGEN ANTAGONISTS; ANDROGENS; ANDROSTENEDIONE; ANIMALS; BETA-GALACTOSIDASE; CELL LINE; DIHYDROTESTOSTERONE; ESTRADIOL; FLUTAMIDE; GENES, REPORTER; IMIDAZOLES; IMIDAZOLIDINES; LUCIFERASES; MALE; POINT MUTATION; PROGESTERONE; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RECOMBINANT FUSION PROTEINS; TRANSFECTION;

EID: 0030877225     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995 [published erratum appears in CA Cancer J. Clin., 45: 127-128, 1995]. CA Cancer J. Clin., 45: 8-30, 1995.
2. Isaacs, J. T., and Kyprianou, N. Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. Urol. Res., 15: 133-138, 1987.
3. Catalona, W. J. Management of cancer of the prostate. N. Engl. J. Med., 331: 996-1004, 1994.
4. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., and Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma [published erratum appears in N. Engl. J. Med., 321: 1420, 1989]. N. Engl. J. Med., 321: 419-424, 1989.
5. Dawson, N. A. Treatment of progressive metastatic prostate cancer. Oncology, 7: 17-24, 1993.
6. Mahler, C., Verhelst, J., and Denis, L. Ketoconazole and liarozole in the treatment of advanced prostatic cancer. Cancer (Phila.), 71: 1068-1073, 1993.
7. Chang, A. Y., Bennett, J. M., Pandya, K. J., Asbury, R., and McCune, C. A study of aminoglutethimide and hydrocortisone in patients with advanced and refractory prostate carcinoma. Am. J. Clin. Oncol., 12: 358-360, 1989.
8. Fossa, S. D., Hosbach, G., and Paus, E. Flutamide in hormone-resistant prostatic cancer. J. Urol., 144: 1411-1414, 1990.
9. van der Kwast, T. H., Schalken, J., Ruizeveld de Winter, J. A., van Vroonhoven, C. C., Mulder, E., Boersma, W., and Trapman, J. Androgen receptors in endocrine therapy-resistant human prostate cancer. Int. J. Cancer, 48: 189-193, 1991.
10. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res., 55: 3068-3072, 1995.
11. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
12. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med., 332: 1393-1398, 1995.
13. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
14. Suzuki, H., Sato, N., Watabe, Y., Masai, M., Seino, S., and Shimazaki, J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol., 46: 759-765, 1993.
15. Gaddipati, J. P., McLeod, D. G., Heidenberg, H. B., Sesterhenn, I. A., Finger, M. J., Moul, J. W., and Srivastava, S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res., 54: 2861-2864, 1994.
16. Scher, H. I., and Kelly, W. K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566-1572, 1993.
17. Wilding, G., Chen, M., and Gelmann, E. P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate, 14: 103-115, 1989.
18. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
19. Brinkmann, A. O., Faber, P. W., van Rooij, H. C., Kuiper, G. G., Ris, C., Klaassen, P., van der Korput, J. A., Voorhorst, M. M., van Laar, J. H., Mulder, E., and Trapman, J. The human androgen receptor: domain structure, genomic organization and regulation of expression. J. Steroid Biochem., 34: 307-310, 1989.
20. Nordeen, S. K. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques, 6: 454-458, 1988.
21. Rohl, H. F., Beuke, H. P., and Rhl, H. F. Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer. Scand. J. Urol. Nephrol., 26: 11-14, 1992.
22. Geller, J. Basis for hormonal management of advanced prostate cancer. Cancer (Phila.), 71: 1039-1045, 1993.
23. Ris-Stalpers, C., Verleun-Mooijman, M. C., Trapman, J., and Brinkmann, A. O. Threonine on amino acid position 868 in the human androgen receptor is essential for androgen binding specificity and functional activity. Biochem. Biophys. Res. Commun., 196: 173-180, 1993.
24. Peterziel, H., Culig, Z., Stober, J., Hobisch, A., Radmayr, C., Bartsch, G., Klocker, H., and Cato, A. C. Mutant androgen receptors in prostatic tumors distinguish between amino acid sequence requirements for transactivation and ligand binding. Int. J. Cancer, 63: 544-550, 1995.
25. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., and Mulder, E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry, 31: 2393-2399, 1992.
26. Wong, C., Kelce, W. R., Sar, M., and Wilson, E. M. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J. Biol. Chem., 270: 19998-20003, 1995.
27. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T., and Kallioniemi, O. P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57: 314-319, 1997.
28. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A., Tompkins, A., Steinberg, S., Figg, W. D., Linehan, W. M., and Myers, C. E. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer [published erratum appears in J. Natl. Cancer Inst., 86: 463, 1994]. J. Natl. Cancer Inst., 86: 222-227, 1994.
29. Belanger, A., Giasson, M., Couture, J., Dupont, A., Cusan, L., and Labrie, F. Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate, 12: 79-84, 1988.
30. Scher, H. I., Zhang, Z. F., Nanus, D., and Kelly, W. K. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology, 47: 61-69, 1996.
31. Small, E. J., and Carroll, P. R. Prostate-specific antigen decline after Casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology, 43: 408-410, 1994.